A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the activity of raltitrexed and ZD1839
versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by
estimating progression free survival (PFS) in each treatment arm.